SlideShare una empresa de Scribd logo
1 de 36
Opioids: A Public Health Emergency
-National Summit on Opioid Safety-
     Group Health Cooperative
            Nov 1, 2012
       Gary M. Franklin, MD, MPH
          Research Professor
  Departments of Environmental Health,
     Neurology, and Health Services
        University of Washington
           Medical Director
    Washington State Department of
         Labor and Industries
DISCLOSURES




Gary Franklin has disclosed no financial
relationships that may pose a conflict of interest

There will be no unannounced disclosures of off-
label use of drugs, biologics or medical devices
"To write prescriptions is easy,
but to come to an understanding with
people is hard."
-- Franz Kafka, “A Country Doctor”
“We can’t solve problems by
using the same kind of
thinking we used when we
created them”
Change in National Norms for Use of Opioids
        for Chronic, Non-cancer Pain

 By the late 1990s, at least 20 states
  passed new laws, regulations, or
  policies moving from near prohibition
  of opioids to use without dosing
  guidance
    WA law: “No disciplinary action will be taken
     against a practitioner based solely on the
     quantity and/or frequency of opioids
     prescribed.” (WAC 246-919-830, 12/1999)
 Laws were based on weak science and
  good experience with cancer pain


  WAC Washington Administrative Code
   5
Similarities Between Illicit & Prescription Drugs
Portenoy and Foley
           Pain 1986; 25: 171-186
 Retrospective case series chronic, non-cancer pain
 N=38; 19 Rx for at least 4 years
 2/3 < 20 mg MED/day; 4> 40 mg MED/day
 24/38 acceptable pain relief
 No gain in social function or employment could be
  documented
 Concluded: “Opioid maintenance therapy can be a
  safe, salutary and more humane alternative…”

By 2006, over 10,000 WA citizens were taking over 120
 mg/day MED
Dentists and Emergency Medicine Physicians were the
main prescribers for patients 5-29 years of age
        5.5 million prescriptions were prescribed to children and teens (19 years and under) in 2009


                                  900

                                  800

                                  700

                                  600
        Rate per 10,000 persons




                                                                                                              GP/FM/DO
                                  500
                                                                                                              IM
                                  400                                                                         DENT
                                                                                                              ORTH SURG
                                  300
                                                                                                              EM
                                  200

                                  100

                                   0
                                        0-4   5-9   10-14   15-19    20-24      25-29   30-39   40-59   60+
                                                                    Age Group


Source: IMS Vector ®One National, TPT 06-30-10 Opioids Rate 2009
Limitations of Long-term (>3 Months)
                      Opioid Therapy

 Overall, the evidence for long-term analgesic efficacy
  is weak
 Putative mechanisms for failed opioid analgesia may
  be related to rampant tolerance
 The premise that tolerance can always be overcome
  by dose escalation is now questioned
 100% of patients on opioids chronically develop
  dependence




  Ballantyne J. Pain Physician 2007;10:479-91
   9
Opioid-Related Deaths,
Washington State Workers’ Compensation, 1992–2005

            14
                                 Definite                Probable    Possible
            12
            10
                 8
   Deaths




                 6
                 4
                 2
                 0
                       „95            „96               „97    „98    „99       „00   „01   „02

                                                              Year

        Franklin GM, et al, Am J Ind Med 2005;48:91-9
            10
State mortality varies by regulatory
environment
Paulozzi and Stier, J Publ Health Pol 2010; 31:
422-32
 Per capita usage of opioids in NY 2/3 that in
       PA
 Drug overdose deaths 1.6 fold higher in PA
  compared to NY
 PDMP in NY better funded and uses
  serialized, tamperproof Rx forms

But mortality rates probably not affected by
mandatory education alone
Opioid issues new cause of
successful malpractice claims
ASOA Closed Claims Database-N=8954
  50/295 medication management issues for CNCP
    59% inappropriate medication management
    24% high risk of misuse
    57% death
 Fitzgibbon et al, Anesthesiology 2010; 112: 948-56
Washington Agency Medical Directors’
               Opioid Dosing Guidelines

 Developed with clinical pain experts in 2006
 Implemented April 1, 2007
 First guideline to emphasize dosing guidance
 Educational pilot, not new standard or rule
 National Guideline Clearinghouse
   http://www.guideline.gov/content.aspx?id=23792&search=wa+opioids




     13
                     www.agencymeddirectors.wa.gov
Washington Agency Medical Directors’
                Opioid Dosing Guidelines

 Part I – If patient has not had clear improvement
 in pain AND function at 120 mg MED (morphine
 equivalent dose) , “take a deep breath”
   If needed, get one-time pain management consultation
   (certified in pain, neurology, or psychiatry)
 Part II – Guidance for patients already on very
 high doses >120 mg MED




      14
                   www.agencymeddirectors.wa.gov
Guidance for Primary Care Providers on Safe and
Effective Use of Opioids for Chronic Non-cancer Pain

 Establish an opioid treatment agreement
 Screen for
    Prior or current substance abuse
    Depression
 Use random urine drug screening judiciously
    Shows patient is taking prescribed drugs
    Identifies non-prescribed drugs
 Do not use concomitant sedative-hypnotics
 Track pain and function to recognize tolerance
 Seek help if dose reaches 120 mg MED, and pain and
  function have not substantially improved

  http://www.agencymeddirectors.wa.gov/opioiddosing.asp
    15
  MED, Morphine equivalent dosec
Open-source Tools Added to June 2010
Update of Opioid Dosing Guidelines
   Opioid Risk Tool: Screen for past and current
    substance abuse
   CAGE-AID screen for alcohol or drug abuse
   Patient Health Questionnaire-9 screen for depression
   2-question tool for tracking pain and function
   Advice on urine drug testing




                                                               CAGE, “cut down” “annoyed” “guilty” “eye-opener”



     16
    http://www.agencymeddirectors.wa.gov/opioiddosing.asp#DC
CDC recommendations-2009
 For practitioners, public payers, and insurers
 Seek help at 120 mg/day MED if pain and
  function not improving
 http://www.cdc.gov/HomeandRecreationalSafety/pdf/p
  oision-issue-brief.pdf
WA State Opioid Dosing Guideline
contributes to reversal of opioid epidemic

 Franklin GM, Mai J, Turner J, et al. Bending the
 prescription opioid dosing and mortality curves:
 impact of the Washington State Opioid Dosing
 Guideline. Am J Ind Med 2012; 55: 325-31
10-Q3
                                                                                                                      2010 Q1
                                                                                                                  10-Q1
                                                                                                                      2009 Q3
                                                                                                                  09-Q3
                                                                                                                      2009 Q1
                                                                                                                  09-Q1
Washington Workers‟ Compensation, 1996–2010




                                                                                                                      2008 Q3
                                                                                                                  08-Q3
                                                                                                                      2008 Q1
                                                                                                                  08-Q1
                                                                                                                      2007 Q3
                                                                                                                  07-Q3
                                                                                                                      2007 Q1
                                                                                                                  07-Q1
                                                                                                                      2006 Q3
                                                                                                                  06-Q3
                                                                                                                      2006 Q1
                                                                                                                  06-Q1
                                                          Long-acting opioids




                                                                                                                      2005 Q3
                                                                                                                  05-Q3
                                                                                           Short-acting opioids




                                                                                                                      2005 Q1
                                                                                                                  05-Q1
                                                                                                                      2004 Q3
                                                                                                                  04-Q3
Average Daily Dosage for Opioids,




                                                                                                                      2004 Q1
                                                                                                                  04-Q1
                                                                                                                      2003 Q3
                                                                                                                  03-Q3



                                                                                                                                Year/Quarter
                                                                                                                      2003 Q1
                                                                                                                  03-Q1
                                                                                                                      2002 Q3
                                                                                                                  02-Q3
                                                                                                                      2002 Q1
                                                                                                                  02-Q1
                                                                                                                  01-Q3
                                                                                                                      2001 Q3
                                                                                                                  01-Q1
                                                                                                                      2001 Q1
                                                                                                                  00-Q3
                                                                                                                      2000 Q3
                                                                                                                  00-Q1
                                                                                                                      2000 Q1
                                                                                                                  99-Q3
                                                                                                                      1999 Q3
                                                                                                                  99-Q1
                                                                                                                      1999 Q1
                                                                                                                  98-Q3
                                                                                                                      1998 Q3
                                                                                                                  98-Q1
                                                                                                                      1998 Q1
                                                                                                                  97-Q3
                                                                                                                      1997 Q3
                                                                                                                  97-Q1
                                                                                                                      1997 Q1
                                                                                                                  96-Q3
                                                                                                                      1996 Q3




                                                                                                                                               19
                                                                                                                  96-Q1
                                                                                                                      1996 Q1




                                                                                80
                                                                                     60
                                                                                          40
                                                                                                          20
                                                                                                                  0
                                                    120
                                              140


                                                             100
                                                             MED (mg/day)
WA Workers' Compensation Opioid-related Deaths 1995-2010



                       35
Opioid-related Death




                       30


                       25


                       20


                       15


                       10


                       5


                       0




                                              Possible     Probable     Definite
Unintentional Prescription Opioid Overdose Deaths
               Washington 1995-2010
                              600

                              500
                                                                                                                        420
           Number of deaths




                              400

                              300

                              200

                              100   24


                                0
                                    95

                                         96

                                              97

                                                   98

                                                        99

                                                             00

                                                                   01

                                                                          02

                                                                                03

                                                                                       04

                                                                                             05

                                                                                                    06

                                                                                                         07

                                                                                                              08

                                                                                                                   09

                                                                                                                        10
                                                         Prescription Opioid + alcohol or illicit drug

                                                         Prescription Opioid +/- Other Prescriptions




* Tramadol only deaths included in 2009, but not in prior years.
Source: Washington State Department of Health, Death Certificates
Washington State Legislation: ESHB 2876,
         On Opioid Treatment. 2010

 Repeals current regulation; new regs by June 2011
 Provides specific dosing guidance and guidance
  on consultations, assessments, and tracking
 Signed into law by Governor Gregoire March 25, 2010




   23
Washington State Opioid Treatment
Regulations
  Emphasize tracking patients for improved
   pain AND function
  Emphasize widely agreed-upon best practices
     Screening for substance abuse and other comorbidities
     Prudent use of urine drug screens
     Opioid treatment agreement
     Single pharmacy and single prescriber
  Encourage use of Prescription Monitoring Program-
  begins 1/1/2012
  and Emergency Department Information Exchange,
  when available

   24
What can PCP do to safely and
 effectively use opioids for CNCP
 Opioid treatment agreement
 Screen for prior or current substance
  abuse/misuse (alcohol, illicit drugs, heavy
  tobacco use)
 Screen for depression
 Prudent use of random urine drug screening
  (diversion, non-prescribed drugs)
 Do not use concomitant sedative-hypnotics or
  benzodiazepines
 Track pain and function to recognize tolerance
 Seek help if MED reaches 120 mg and pain
  and function have not substantially improved
 Use State PDMP
Improving Physician Access to
       Pain Specialists in Washington
       State
 Issue
   Moderate capacity problem: not enough pain
    specialists
   Interventional anesthesiologists generally won‟t see
    these patients to assist with opioid issues
 Solution
   Advanced training for primary care to increase
    proficiency
   Telephonic or video consultation with experts
    [Project ECHO at UW
    (http://depts.washington.edu/anesth/care/pain/echo/
    index.shtml)]
    Public payers working on payment codes to
  26
    incentivize these activities
Incent best practices in community settings to
    prevent/treat chronic pain
    Cognitive behavioral therapy
    Graded exercise
    Activity coaching
    Interdisciplinary care
    Care coordination

Centers for Occupational Health and Education will
    expand to 100% of WA injured workers by 2015
Medical Home concept to prevent transition to chronic
    pain, and more adequately treat chronic pain




      27
There is substantial clustering among
   providers on dosing and mortality
CA CWCI study-Swedlow et al, March, 2011: 3% of
  prescribers account for 55% of Schedule II opioid
  Rxs:http://www.cwci.org/research.html
Dhalla et al, Clustering of opioid prescribing and opioid-
  related mortality among family physicians in Ontario. Can
  Fam Physician 2011; 57: e92-96
  Upper quintile of frequent opioid prescribers associated
  with last opioid Rx in 62.7% of public plan beneficiary
  unintentional poisoning deaths
DLI sent letters to all prescribers with any patient on opioid
doses at or above 120 mg/day MED
 Call their attention to AMDG Guidelines and new WA
  state regulations
 Associate medical director will meet with these docs
  personally
Early opioids and disability in WA WC. Spine
2008; 33: 199-204
  Population-based, prospective cohort
  N=1843 workers with acute low back injury
   and at least 4 days lost time
  Baseline interview within 18 days(median)
  14% on disability at one year
  Receipt of opioids for > 7 days, at least 2
   Rxs, or > 150 mg MED doubled risk of 1 year
   disability, after adjustment for
   pain, function, injury severity
Disability generated in workers‟ compensation
   may be a public health problem of the highest
   order

 1954-4% of men 25-54 unemployed
 2010-20% of men 25-54 unemployed
 Federal (SSD) disability-8 million-will be bankrupt in
  7 years
 Workers‟ compensation is likely contributing a large
  proportion of the permanently unemployed/disabled
  to State, Federal and private disability programs
David Leonhardt, Men, Unemployment, and
disability, NYT, 4/8/2011
38% Increase since 2001
Concrete steps to take
 Track high MED and prescribers
 Reverse permissive laws and set dosing standards for
    chronic, non-cancer pain
   Implement AMDG Opioid Dosing Guidelines
    (http://www.agencymeddirectors.wa.gov/opioiddosing.asp)
   Implement Prescription Monitoring Program
   Encourage/incent use of best practices (web-based MED
    calculator, use of state PMPs)
   DO NOT pay for office dispensed opioids
   ID high prescribers and offer assistance
   Incent community-based Rx alternatives (activity coaching and
    graded exercise early, opioid taper/multidisciplinary Rx later)
   Offer assistance (academic detailing, free CME,ECHO)
Unfinished business
 Guidelines for peri-operative use of opioids
 Looming large population dependent/addicted
  from Rx opioids
 Develop guidelines Re tapering
   PCP routine taper; Detox/pain clinic taper +/-
   buprenorphine
 Rx of opioid use disorder/addiction


New WA WC guidelines address these issues
It‟s an emergency, so move ahead
gingerly
If you do something effective to reverse a decade of
bad public policy, you will get pushback: Fauber J.
Follow the money: Pain, policy, and profit. 2/19/12.
   URL:http://www.medpagetoday.com/Neurology/PainManag
   ement/31256
 But remember that the docs in the trenches welcome
assistance, tools, and best practices
       -National survey of PCP network for low income
       patients: 1/3 reported a severe outcome (death
       or life-threatening event); 1/3 do not initiate
       prescribing of opioids*
 WA prescribers are MUCH more concerned about
dependence/addiction than about regulatory scrutiny

      *Leverence RR, et al. J Am Board Fam Med 2011; 24: 551-561
New state policies
Connecticut WC policy-7/1/2012
  The total daily dose of opioids should not be increased above 90mg
  oral MED/day (Morphine Equivalent Dose) unless the patient
  demonstrates measured improvement in function, pain or work
  capacity. Second opinion is recommended if contemplating raising the
  dose above 90 MED/day.

MaineCare (Medicaid)-4/1/2012
  Total 45 day maximum for non-cancer pain

New Mexico-Rule 16.10.14-Proposed rules
Aug, 2012
      A health care practitioner shall, before
  prescribing, ordering, administering or dispensing a controlled
  substance listed in schedule II, III or IV, obtain a patient PMP
  report for the preceding twelve (12) months
THANK YOU!

For electronic copies of this
 presentation, please e-mail
      Melinda Fujiwara
vasudha@u.washington.edu
 For questions or feedback,
           please
    e-mail Gary Franklin
 meddir@u.washington.edu

Más contenido relacionado

La actualidad más candente

Addictive and psychotropic drugs
Addictive and psychotropic drugsAddictive and psychotropic drugs
Addictive and psychotropic drugspurvi gosrani
 
Introduction to community pharmacy.pdf
Introduction to community pharmacy.pdfIntroduction to community pharmacy.pdf
Introduction to community pharmacy.pdfMohamedAliMohamedEli
 
diabetes management by pharmacist
diabetes management by pharmacistdiabetes management by pharmacist
diabetes management by pharmacistmanik chhabra.
 
PATIENT COMPLIANCE
PATIENT COMPLIANCE PATIENT COMPLIANCE
PATIENT COMPLIANCE Amr Flifle
 
COMPILED VERSION Sbh who good pharmacy practice(gpp)
COMPILED VERSION Sbh who good pharmacy practice(gpp)COMPILED VERSION Sbh who good pharmacy practice(gpp)
COMPILED VERSION Sbh who good pharmacy practice(gpp)Sitaram Khadka
 
Pesticides -overview
Pesticides -overviewPesticides -overview
Pesticides -overviewladdha1962
 
Drug abuse and addition
Drug abuse and additionDrug abuse and addition
Drug abuse and additionankitrich
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan DrugsANCY JOSE
 
Professionalism in Clinical Pharmacy Practice
Professionalism in Clinical Pharmacy PracticeProfessionalism in Clinical Pharmacy Practice
Professionalism in Clinical Pharmacy PracticeSitaram Khadka
 
Outpatients and inpatients pharmacy
Outpatients and inpatients pharmacyOutpatients and inpatients pharmacy
Outpatients and inpatients pharmacyOmar Hesham
 
Causality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilanceCausality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilanceGaurav Chhabra
 
Hospital Standards Practice - 3
Hospital Standards Practice - 3Hospital Standards Practice - 3
Hospital Standards Practice - 3Areej Abu Hanieh
 
Pharmacy and scope of pharmacy ppt
Pharmacy and scope of pharmacy pptPharmacy and scope of pharmacy ppt
Pharmacy and scope of pharmacy pptShahnawaz Ahmad
 

La actualidad más candente (20)

Opioid Awareness
Opioid AwarenessOpioid Awareness
Opioid Awareness
 
Pharmacist
PharmacistPharmacist
Pharmacist
 
Addictive and psychotropic drugs
Addictive and psychotropic drugsAddictive and psychotropic drugs
Addictive and psychotropic drugs
 
Methadone Clinical Guidelines
Methadone Clinical GuidelinesMethadone Clinical Guidelines
Methadone Clinical Guidelines
 
Introduction to community pharmacy.pdf
Introduction to community pharmacy.pdfIntroduction to community pharmacy.pdf
Introduction to community pharmacy.pdf
 
Community pharmacy
Community pharmacyCommunity pharmacy
Community pharmacy
 
diabetes management by pharmacist
diabetes management by pharmacistdiabetes management by pharmacist
diabetes management by pharmacist
 
PATIENT COMPLIANCE
PATIENT COMPLIANCE PATIENT COMPLIANCE
PATIENT COMPLIANCE
 
Alcoholism and health
Alcoholism and healthAlcoholism and health
Alcoholism and health
 
COMPILED VERSION Sbh who good pharmacy practice(gpp)
COMPILED VERSION Sbh who good pharmacy practice(gpp)COMPILED VERSION Sbh who good pharmacy practice(gpp)
COMPILED VERSION Sbh who good pharmacy practice(gpp)
 
Pesticides -overview
Pesticides -overviewPesticides -overview
Pesticides -overview
 
Drug abuse and addition
Drug abuse and additionDrug abuse and addition
Drug abuse and addition
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Professionalism in Clinical Pharmacy Practice
Professionalism in Clinical Pharmacy PracticeProfessionalism in Clinical Pharmacy Practice
Professionalism in Clinical Pharmacy Practice
 
Outpatients and inpatients pharmacy
Outpatients and inpatients pharmacyOutpatients and inpatients pharmacy
Outpatients and inpatients pharmacy
 
Causality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilanceCausality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilance
 
Internship report on allied hospital faisalabad
Internship report on allied hospital faisalabadInternship report on allied hospital faisalabad
Internship report on allied hospital faisalabad
 
Hospital Standards Practice - 3
Hospital Standards Practice - 3Hospital Standards Practice - 3
Hospital Standards Practice - 3
 
Pharmacy and scope of pharmacy ppt
Pharmacy and scope of pharmacy pptPharmacy and scope of pharmacy ppt
Pharmacy and scope of pharmacy ppt
 
Drugs of Abuse & Social Consequences
Drugs of Abuse & Social ConsequencesDrugs of Abuse & Social Consequences
Drugs of Abuse & Social Consequences
 

Destacado

PRESCRIPTION OPIOIDS - AN EPIDEMIC OF POOR POLICIES
PRESCRIPTION OPIOIDS - AN EPIDEMIC OF POOR POLICIESPRESCRIPTION OPIOIDS - AN EPIDEMIC OF POOR POLICIES
PRESCRIPTION OPIOIDS - AN EPIDEMIC OF POOR POLICIESIDHDP
 
Gary Franklin
Gary FranklinGary Franklin
Gary FranklinOPUNITE
 
The Opioid Analgesic Epidemic: How it Happened
The Opioid Analgesic Epidemic:  How it HappenedThe Opioid Analgesic Epidemic:  How it Happened
The Opioid Analgesic Epidemic: How it HappenedGroup Health Cooperative
 
Opioid Pharmacology
Opioid PharmacologyOpioid Pharmacology
Opioid Pharmacologyshabeel pn
 
DrugInfo seminar: Opioids and related harms in Aboriginal Australia
DrugInfo seminar: Opioids and related harms in Aboriginal AustraliaDrugInfo seminar: Opioids and related harms in Aboriginal Australia
DrugInfo seminar: Opioids and related harms in Aboriginal AustraliaAustralian Drug Foundation
 
VISN20 Residential Functional Restoration Pain Program
VISN20 Residential Functional Restoration Pain ProgramVISN20 Residential Functional Restoration Pain Program
VISN20 Residential Functional Restoration Pain ProgramLaura M. Tuck, Psy.D
 
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...University of Michigan Injury Center
 
Getting the low down on prescription opioids: Learn how to notice the signs a...
Getting the low down on prescription opioids: Learn how to notice the signs a...Getting the low down on prescription opioids: Learn how to notice the signs a...
Getting the low down on prescription opioids: Learn how to notice the signs a...The Royal Mental Health Centre
 
2014 opioids eastern or ems conference
2014 opioids eastern or ems conference2014 opioids eastern or ems conference
2014 opioids eastern or ems conferenceRobert Cole
 
Opioid Abuse in Chronic Pain
Opioid Abuse in Chronic PainOpioid Abuse in Chronic Pain
Opioid Abuse in Chronic PainPaul Coelho, MD
 
Opioids Drugs
Opioids DrugsOpioids Drugs
Opioids DrugsKhalid
 
Rx16 presummit 200_empower_veteransprogram
Rx16 presummit 200_empower_veteransprogramRx16 presummit 200_empower_veteransprogram
Rx16 presummit 200_empower_veteransprogramOPUNITE
 
Wed frieden web-version_rx_od (unite) - apr 8 -video_external
Wed frieden web-version_rx_od (unite) - apr 8 -video_externalWed frieden web-version_rx_od (unite) - apr 8 -video_external
Wed frieden web-version_rx_od (unite) - apr 8 -video_externalOPUNITE
 
Rx16 pharma tues_200_1_kelly_2ream_3shanehsaz
Rx16 pharma tues_200_1_kelly_2ream_3shanehsazRx16 pharma tues_200_1_kelly_2ream_3shanehsaz
Rx16 pharma tues_200_1_kelly_2ream_3shanehsazOPUNITE
 
Web only rx16 len tues_1115_group
Web only rx16 len tues_1115_groupWeb only rx16 len tues_1115_group
Web only rx16 len tues_1115_groupOPUNITE
 
Opioids
Opioids		Opioids
Opioids Khalid
 

Destacado (20)

PRESCRIPTION OPIOIDS - AN EPIDEMIC OF POOR POLICIES
PRESCRIPTION OPIOIDS - AN EPIDEMIC OF POOR POLICIESPRESCRIPTION OPIOIDS - AN EPIDEMIC OF POOR POLICIES
PRESCRIPTION OPIOIDS - AN EPIDEMIC OF POOR POLICIES
 
Gary Franklin
Gary FranklinGary Franklin
Gary Franklin
 
Chronic Opioid Therapy
Chronic Opioid TherapyChronic Opioid Therapy
Chronic Opioid Therapy
 
The Opioid Analgesic Epidemic: How it Happened
The Opioid Analgesic Epidemic:  How it HappenedThe Opioid Analgesic Epidemic:  How it Happened
The Opioid Analgesic Epidemic: How it Happened
 
Opioid Pharmacology
Opioid PharmacologyOpioid Pharmacology
Opioid Pharmacology
 
DrugInfo seminar: Opioids and related harms in Aboriginal Australia
DrugInfo seminar: Opioids and related harms in Aboriginal AustraliaDrugInfo seminar: Opioids and related harms in Aboriginal Australia
DrugInfo seminar: Opioids and related harms in Aboriginal Australia
 
Prescribing Opioids in the ED
Prescribing Opioids in the EDPrescribing Opioids in the ED
Prescribing Opioids in the ED
 
VISN20 Residential Functional Restoration Pain Program
VISN20 Residential Functional Restoration Pain ProgramVISN20 Residential Functional Restoration Pain Program
VISN20 Residential Functional Restoration Pain Program
 
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...
Non-medical Use and Medical Misuse of Opioids during Adolescence by Carol J B...
 
Getting the low down on prescription opioids: Learn how to notice the signs a...
Getting the low down on prescription opioids: Learn how to notice the signs a...Getting the low down on prescription opioids: Learn how to notice the signs a...
Getting the low down on prescription opioids: Learn how to notice the signs a...
 
2014 opioids eastern or ems conference
2014 opioids eastern or ems conference2014 opioids eastern or ems conference
2014 opioids eastern or ems conference
 
Opioid Abuse in Chronic Pain
Opioid Abuse in Chronic PainOpioid Abuse in Chronic Pain
Opioid Abuse in Chronic Pain
 
Opioids
OpioidsOpioids
Opioids
 
National Summit On Opioid Safety
National Summit On Opioid  SafetyNational Summit On Opioid  Safety
National Summit On Opioid Safety
 
Opioids Drugs
Opioids DrugsOpioids Drugs
Opioids Drugs
 
Rx16 presummit 200_empower_veteransprogram
Rx16 presummit 200_empower_veteransprogramRx16 presummit 200_empower_veteransprogram
Rx16 presummit 200_empower_veteransprogram
 
Wed frieden web-version_rx_od (unite) - apr 8 -video_external
Wed frieden web-version_rx_od (unite) - apr 8 -video_externalWed frieden web-version_rx_od (unite) - apr 8 -video_external
Wed frieden web-version_rx_od (unite) - apr 8 -video_external
 
Rx16 pharma tues_200_1_kelly_2ream_3shanehsaz
Rx16 pharma tues_200_1_kelly_2ream_3shanehsazRx16 pharma tues_200_1_kelly_2ream_3shanehsaz
Rx16 pharma tues_200_1_kelly_2ream_3shanehsaz
 
Web only rx16 len tues_1115_group
Web only rx16 len tues_1115_groupWeb only rx16 len tues_1115_group
Web only rx16 len tues_1115_group
 
Opioids
Opioids		Opioids
Opioids
 

Similar a Opioid Safety Summit: Reversing the Epidemic

Breaching Boundaries Ethics 20101116 V3x
Breaching Boundaries   Ethics 20101116 V3xBreaching Boundaries   Ethics 20101116 V3x
Breaching Boundaries Ethics 20101116 V3xpdenayer
 
Breaching boundaries : The Health Versus Direct Marketing Boundary
Breaching boundaries : The Health Versus Direct Marketing BoundaryBreaching boundaries : The Health Versus Direct Marketing Boundary
Breaching boundaries : The Health Versus Direct Marketing BoundaryPierre De Nayer
 
Fell.mhscn 2010 2
Fell.mhscn 2010 2Fell.mhscn 2010 2
Fell.mhscn 2010 2MHSCN
 
The role of primary care providers in occupational health
The role of primary care providers in occupational healthThe role of primary care providers in occupational health
The role of primary care providers in occupational healthHealth and Labour
 
A tale of_two-states-final
A tale of_two-states-finalA tale of_two-states-final
A tale of_two-states-finalOPUNITE
 
CAND Posters 2011
CAND Posters 2011CAND Posters 2011
CAND Posters 2011CCNM
 
CAND POSTERS 2011
CAND POSTERS 2011CAND POSTERS 2011
CAND POSTERS 2011CCNM
 
New Drug Opportunity Assessments Strat Planning For Future Success
New Drug Opportunity Assessments  Strat Planning For Future SuccessNew Drug Opportunity Assessments  Strat Planning For Future Success
New Drug Opportunity Assessments Strat Planning For Future SuccessPharmacision LLC
 
Ph 2 paulozzi paone_kelly
Ph 2 paulozzi paone_kellyPh 2 paulozzi paone_kelly
Ph 2 paulozzi paone_kellyOPUNITE
 
Healthcare's Wage and Hour Claim Challenge
Healthcare's Wage and Hour Claim ChallengeHealthcare's Wage and Hour Claim Challenge
Healthcare's Wage and Hour Claim ChallengeKendal Peterson
 

Similar a Opioid Safety Summit: Reversing the Epidemic (12)

Breaching Boundaries Ethics 20101116 V3x
Breaching Boundaries   Ethics 20101116 V3xBreaching Boundaries   Ethics 20101116 V3x
Breaching Boundaries Ethics 20101116 V3x
 
Breaching boundaries : The Health Versus Direct Marketing Boundary
Breaching boundaries : The Health Versus Direct Marketing BoundaryBreaching boundaries : The Health Versus Direct Marketing Boundary
Breaching boundaries : The Health Versus Direct Marketing Boundary
 
Fell.mhscn 2010 2
Fell.mhscn 2010 2Fell.mhscn 2010 2
Fell.mhscn 2010 2
 
The role of primary care providers in occupational health
The role of primary care providers in occupational healthThe role of primary care providers in occupational health
The role of primary care providers in occupational health
 
A tale of_two-states-final
A tale of_two-states-finalA tale of_two-states-final
A tale of_two-states-final
 
CAND Posters 2011
CAND Posters 2011CAND Posters 2011
CAND Posters 2011
 
CAND POSTERS 2011
CAND POSTERS 2011CAND POSTERS 2011
CAND POSTERS 2011
 
New Drug Opportunity Assessments Strat Planning For Future Success
New Drug Opportunity Assessments  Strat Planning For Future SuccessNew Drug Opportunity Assessments  Strat Planning For Future Success
New Drug Opportunity Assessments Strat Planning For Future Success
 
61 Minutes AAEP 2010
61 Minutes AAEP 201061 Minutes AAEP 2010
61 Minutes AAEP 2010
 
Ph 2 paulozzi paone_kelly
Ph 2 paulozzi paone_kellyPh 2 paulozzi paone_kelly
Ph 2 paulozzi paone_kelly
 
Darzi10mins
Darzi10minsDarzi10mins
Darzi10mins
 
Healthcare's Wage and Hour Claim Challenge
Healthcare's Wage and Hour Claim ChallengeHealthcare's Wage and Hour Claim Challenge
Healthcare's Wage and Hour Claim Challenge
 

Más de Group Health Cooperative

Prevention of Type 2 Diabetes and Stemming the Tide
Prevention of Type 2 Diabetes and Stemming the TidePrevention of Type 2 Diabetes and Stemming the Tide
Prevention of Type 2 Diabetes and Stemming the TideGroup Health Cooperative
 
Best Practices for Managing High-Risk Clinical Populations
Best Practices for Managing High-Risk Clinical PopulationsBest Practices for Managing High-Risk Clinical Populations
Best Practices for Managing High-Risk Clinical PopulationsGroup Health Cooperative
 
Using the Electronic Medical Record to Drive Improved Patient Outcomes
Using the Electronic Medical Record to Drive Improved Patient Outcomes Using the Electronic Medical Record to Drive Improved Patient Outcomes
Using the Electronic Medical Record to Drive Improved Patient Outcomes Group Health Cooperative
 
Barriers to opioid monitoring in primary care
Barriers to opioid monitoring in primary careBarriers to opioid monitoring in primary care
Barriers to opioid monitoring in primary careGroup Health Cooperative
 
Implementing chronic opioid therapy guidelines at Group Health Cooperative
Implementing chronic opioid therapy guidelines at Group Health CooperativeImplementing chronic opioid therapy guidelines at Group Health Cooperative
Implementing chronic opioid therapy guidelines at Group Health CooperativeGroup Health Cooperative
 
Principles for more cautious and selective opioid prescribing for chronic non...
Principles for more cautious and selective opioid prescribing for chronic non...Principles for more cautious and selective opioid prescribing for chronic non...
Principles for more cautious and selective opioid prescribing for chronic non...Group Health Cooperative
 
State of the evidence on chronic opioid therapy and risk mitigation
State of the evidence on chronic opioid therapy and risk mitigation State of the evidence on chronic opioid therapy and risk mitigation
State of the evidence on chronic opioid therapy and risk mitigation Group Health Cooperative
 
The Medical Home Model: Patient Centered Care
The Medical Home Model: Patient Centered CareThe Medical Home Model: Patient Centered Care
The Medical Home Model: Patient Centered CareGroup Health Cooperative
 
Emergency Department/Hospital Inpatient Initiative
Emergency Department/Hospital Inpatient InitiativeEmergency Department/Hospital Inpatient Initiative
Emergency Department/Hospital Inpatient InitiativeGroup Health Cooperative
 

Más de Group Health Cooperative (16)

Prevention of Type 2 Diabetes and Stemming the Tide
Prevention of Type 2 Diabetes and Stemming the TidePrevention of Type 2 Diabetes and Stemming the Tide
Prevention of Type 2 Diabetes and Stemming the Tide
 
Best Practices for Managing High-Risk Clinical Populations
Best Practices for Managing High-Risk Clinical PopulationsBest Practices for Managing High-Risk Clinical Populations
Best Practices for Managing High-Risk Clinical Populations
 
Using the Electronic Medical Record to Drive Improved Patient Outcomes
Using the Electronic Medical Record to Drive Improved Patient Outcomes Using the Electronic Medical Record to Drive Improved Patient Outcomes
Using the Electronic Medical Record to Drive Improved Patient Outcomes
 
Becoming a Learning Healthcare System
Becoming a Learning Healthcare SystemBecoming a Learning Healthcare System
Becoming a Learning Healthcare System
 
Learning Health Care Systems
Learning Health Care SystemsLearning Health Care Systems
Learning Health Care Systems
 
Barriers to opioid monitoring in primary care
Barriers to opioid monitoring in primary careBarriers to opioid monitoring in primary care
Barriers to opioid monitoring in primary care
 
Implementing chronic opioid therapy guidelines at Group Health Cooperative
Implementing chronic opioid therapy guidelines at Group Health CooperativeImplementing chronic opioid therapy guidelines at Group Health Cooperative
Implementing chronic opioid therapy guidelines at Group Health Cooperative
 
Principles for more cautious and selective opioid prescribing for chronic non...
Principles for more cautious and selective opioid prescribing for chronic non...Principles for more cautious and selective opioid prescribing for chronic non...
Principles for more cautious and selective opioid prescribing for chronic non...
 
State of the evidence on chronic opioid therapy and risk mitigation
State of the evidence on chronic opioid therapy and risk mitigation State of the evidence on chronic opioid therapy and risk mitigation
State of the evidence on chronic opioid therapy and risk mitigation
 
Shared Decision Making
Shared Decision MakingShared Decision Making
Shared Decision Making
 
Wennberg at Group Health 3-25-11
Wennberg at Group Health 3-25-11Wennberg at Group Health 3-25-11
Wennberg at Group Health 3-25-11
 
The Medical Home Model: Patient Centered Care
The Medical Home Model: Patient Centered CareThe Medical Home Model: Patient Centered Care
The Medical Home Model: Patient Centered Care
 
Improving the Value of High-End Imaging
Improving the Value of High-End ImagingImproving the Value of High-End Imaging
Improving the Value of High-End Imaging
 
Shared Decision Making
Shared Decision MakingShared Decision Making
Shared Decision Making
 
Emergency Department/Hospital Inpatient Initiative
Emergency Department/Hospital Inpatient InitiativeEmergency Department/Hospital Inpatient Initiative
Emergency Department/Hospital Inpatient Initiative
 
Medical Home Model: Patient Centered Care
Medical Home Model: Patient Centered CareMedical Home Model: Patient Centered Care
Medical Home Model: Patient Centered Care
 

Último

Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991RKavithamani
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Krashi Coaching
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3JemimahLaneBuaron
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxmanuelaromero2013
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13Steve Thomason
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Sapana Sha
 
Concept of Vouching. B.Com(Hons) /B.Compdf
Concept of Vouching. B.Com(Hons) /B.CompdfConcept of Vouching. B.Com(Hons) /B.Compdf
Concept of Vouching. B.Com(Hons) /B.CompdfUmakantAnnand
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAssociation for Project Management
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docxPoojaSen20
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesFatimaKhan178732
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentInMediaRes1
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application ) Sakshi Ghasle
 
PSYCHIATRIC History collection FORMAT.pptx
PSYCHIATRIC   History collection FORMAT.pptxPSYCHIATRIC   History collection FORMAT.pptx
PSYCHIATRIC History collection FORMAT.pptxPoojaSen20
 

Último (20)

Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptx
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
 
Concept of Vouching. B.Com(Hons) /B.Compdf
Concept of Vouching. B.Com(Hons) /B.CompdfConcept of Vouching. B.Com(Hons) /B.Compdf
Concept of Vouching. B.Com(Hons) /B.Compdf
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across Sectors
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docx
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and Actinides
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media Component
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application )
 
PSYCHIATRIC History collection FORMAT.pptx
PSYCHIATRIC   History collection FORMAT.pptxPSYCHIATRIC   History collection FORMAT.pptx
PSYCHIATRIC History collection FORMAT.pptx
 

Opioid Safety Summit: Reversing the Epidemic

  • 1. Opioids: A Public Health Emergency -National Summit on Opioid Safety- Group Health Cooperative Nov 1, 2012 Gary M. Franklin, MD, MPH Research Professor Departments of Environmental Health, Neurology, and Health Services University of Washington Medical Director Washington State Department of Labor and Industries
  • 2. DISCLOSURES Gary Franklin has disclosed no financial relationships that may pose a conflict of interest There will be no unannounced disclosures of off- label use of drugs, biologics or medical devices
  • 3. "To write prescriptions is easy, but to come to an understanding with people is hard." -- Franz Kafka, “A Country Doctor”
  • 4. “We can’t solve problems by using the same kind of thinking we used when we created them”
  • 5. Change in National Norms for Use of Opioids for Chronic, Non-cancer Pain  By the late 1990s, at least 20 states passed new laws, regulations, or policies moving from near prohibition of opioids to use without dosing guidance  WA law: “No disciplinary action will be taken against a practitioner based solely on the quantity and/or frequency of opioids prescribed.” (WAC 246-919-830, 12/1999)  Laws were based on weak science and good experience with cancer pain WAC Washington Administrative Code 5
  • 6. Similarities Between Illicit & Prescription Drugs
  • 7. Portenoy and Foley Pain 1986; 25: 171-186  Retrospective case series chronic, non-cancer pain  N=38; 19 Rx for at least 4 years  2/3 < 20 mg MED/day; 4> 40 mg MED/day  24/38 acceptable pain relief  No gain in social function or employment could be documented  Concluded: “Opioid maintenance therapy can be a safe, salutary and more humane alternative…” By 2006, over 10,000 WA citizens were taking over 120 mg/day MED
  • 8. Dentists and Emergency Medicine Physicians were the main prescribers for patients 5-29 years of age 5.5 million prescriptions were prescribed to children and teens (19 years and under) in 2009 900 800 700 600 Rate per 10,000 persons GP/FM/DO 500 IM 400 DENT ORTH SURG 300 EM 200 100 0 0-4 5-9 10-14 15-19 20-24 25-29 30-39 40-59 60+ Age Group Source: IMS Vector ®One National, TPT 06-30-10 Opioids Rate 2009
  • 9. Limitations of Long-term (>3 Months) Opioid Therapy  Overall, the evidence for long-term analgesic efficacy is weak  Putative mechanisms for failed opioid analgesia may be related to rampant tolerance  The premise that tolerance can always be overcome by dose escalation is now questioned  100% of patients on opioids chronically develop dependence Ballantyne J. Pain Physician 2007;10:479-91 9
  • 10. Opioid-Related Deaths, Washington State Workers’ Compensation, 1992–2005 14 Definite Probable Possible 12 10 8 Deaths 6 4 2 0 „95 „96 „97 „98 „99 „00 „01 „02 Year Franklin GM, et al, Am J Ind Med 2005;48:91-9 10
  • 11. State mortality varies by regulatory environment Paulozzi and Stier, J Publ Health Pol 2010; 31: 422-32  Per capita usage of opioids in NY 2/3 that in PA  Drug overdose deaths 1.6 fold higher in PA compared to NY  PDMP in NY better funded and uses serialized, tamperproof Rx forms But mortality rates probably not affected by mandatory education alone
  • 12. Opioid issues new cause of successful malpractice claims ASOA Closed Claims Database-N=8954  50/295 medication management issues for CNCP  59% inappropriate medication management  24% high risk of misuse  57% death Fitzgibbon et al, Anesthesiology 2010; 112: 948-56
  • 13. Washington Agency Medical Directors’ Opioid Dosing Guidelines  Developed with clinical pain experts in 2006  Implemented April 1, 2007  First guideline to emphasize dosing guidance  Educational pilot, not new standard or rule  National Guideline Clearinghouse  http://www.guideline.gov/content.aspx?id=23792&search=wa+opioids 13 www.agencymeddirectors.wa.gov
  • 14. Washington Agency Medical Directors’ Opioid Dosing Guidelines  Part I – If patient has not had clear improvement in pain AND function at 120 mg MED (morphine equivalent dose) , “take a deep breath”  If needed, get one-time pain management consultation (certified in pain, neurology, or psychiatry)  Part II – Guidance for patients already on very high doses >120 mg MED 14 www.agencymeddirectors.wa.gov
  • 15. Guidance for Primary Care Providers on Safe and Effective Use of Opioids for Chronic Non-cancer Pain  Establish an opioid treatment agreement  Screen for  Prior or current substance abuse  Depression  Use random urine drug screening judiciously  Shows patient is taking prescribed drugs  Identifies non-prescribed drugs  Do not use concomitant sedative-hypnotics  Track pain and function to recognize tolerance  Seek help if dose reaches 120 mg MED, and pain and function have not substantially improved http://www.agencymeddirectors.wa.gov/opioiddosing.asp 15 MED, Morphine equivalent dosec
  • 16. Open-source Tools Added to June 2010 Update of Opioid Dosing Guidelines  Opioid Risk Tool: Screen for past and current substance abuse  CAGE-AID screen for alcohol or drug abuse  Patient Health Questionnaire-9 screen for depression  2-question tool for tracking pain and function  Advice on urine drug testing CAGE, “cut down” “annoyed” “guilty” “eye-opener” 16 http://www.agencymeddirectors.wa.gov/opioiddosing.asp#DC
  • 17. CDC recommendations-2009  For practitioners, public payers, and insurers  Seek help at 120 mg/day MED if pain and function not improving  http://www.cdc.gov/HomeandRecreationalSafety/pdf/p oision-issue-brief.pdf
  • 18. WA State Opioid Dosing Guideline contributes to reversal of opioid epidemic Franklin GM, Mai J, Turner J, et al. Bending the prescription opioid dosing and mortality curves: impact of the Washington State Opioid Dosing Guideline. Am J Ind Med 2012; 55: 325-31
  • 19. 10-Q3 2010 Q1 10-Q1 2009 Q3 09-Q3 2009 Q1 09-Q1 Washington Workers‟ Compensation, 1996–2010 2008 Q3 08-Q3 2008 Q1 08-Q1 2007 Q3 07-Q3 2007 Q1 07-Q1 2006 Q3 06-Q3 2006 Q1 06-Q1 Long-acting opioids 2005 Q3 05-Q3 Short-acting opioids 2005 Q1 05-Q1 2004 Q3 04-Q3 Average Daily Dosage for Opioids, 2004 Q1 04-Q1 2003 Q3 03-Q3 Year/Quarter 2003 Q1 03-Q1 2002 Q3 02-Q3 2002 Q1 02-Q1 01-Q3 2001 Q3 01-Q1 2001 Q1 00-Q3 2000 Q3 00-Q1 2000 Q1 99-Q3 1999 Q3 99-Q1 1999 Q1 98-Q3 1998 Q3 98-Q1 1998 Q1 97-Q3 1997 Q3 97-Q1 1997 Q1 96-Q3 1996 Q3 19 96-Q1 1996 Q1 80 60 40 20 0 120 140 100 MED (mg/day)
  • 20. WA Workers' Compensation Opioid-related Deaths 1995-2010 35 Opioid-related Death 30 25 20 15 10 5 0 Possible Probable Definite
  • 21. Unintentional Prescription Opioid Overdose Deaths Washington 1995-2010 600 500 420 Number of deaths 400 300 200 100 24 0 95 96 97 98 99 00 01 02 03 04 05 06 07 08 09 10 Prescription Opioid + alcohol or illicit drug Prescription Opioid +/- Other Prescriptions * Tramadol only deaths included in 2009, but not in prior years. Source: Washington State Department of Health, Death Certificates
  • 22.
  • 23. Washington State Legislation: ESHB 2876, On Opioid Treatment. 2010  Repeals current regulation; new regs by June 2011  Provides specific dosing guidance and guidance on consultations, assessments, and tracking  Signed into law by Governor Gregoire March 25, 2010 23
  • 24. Washington State Opioid Treatment Regulations  Emphasize tracking patients for improved pain AND function  Emphasize widely agreed-upon best practices  Screening for substance abuse and other comorbidities  Prudent use of urine drug screens  Opioid treatment agreement  Single pharmacy and single prescriber  Encourage use of Prescription Monitoring Program- begins 1/1/2012 and Emergency Department Information Exchange, when available 24
  • 25. What can PCP do to safely and effectively use opioids for CNCP  Opioid treatment agreement  Screen for prior or current substance abuse/misuse (alcohol, illicit drugs, heavy tobacco use)  Screen for depression  Prudent use of random urine drug screening (diversion, non-prescribed drugs)  Do not use concomitant sedative-hypnotics or benzodiazepines  Track pain and function to recognize tolerance  Seek help if MED reaches 120 mg and pain and function have not substantially improved  Use State PDMP
  • 26. Improving Physician Access to Pain Specialists in Washington State  Issue  Moderate capacity problem: not enough pain specialists  Interventional anesthesiologists generally won‟t see these patients to assist with opioid issues  Solution  Advanced training for primary care to increase proficiency  Telephonic or video consultation with experts [Project ECHO at UW (http://depts.washington.edu/anesth/care/pain/echo/ index.shtml)] Public payers working on payment codes to 26 incentivize these activities
  • 27. Incent best practices in community settings to prevent/treat chronic pain  Cognitive behavioral therapy  Graded exercise  Activity coaching  Interdisciplinary care  Care coordination Centers for Occupational Health and Education will expand to 100% of WA injured workers by 2015 Medical Home concept to prevent transition to chronic pain, and more adequately treat chronic pain 27
  • 28. There is substantial clustering among providers on dosing and mortality CA CWCI study-Swedlow et al, March, 2011: 3% of prescribers account for 55% of Schedule II opioid Rxs:http://www.cwci.org/research.html Dhalla et al, Clustering of opioid prescribing and opioid- related mortality among family physicians in Ontario. Can Fam Physician 2011; 57: e92-96 Upper quintile of frequent opioid prescribers associated with last opioid Rx in 62.7% of public plan beneficiary unintentional poisoning deaths DLI sent letters to all prescribers with any patient on opioid doses at or above 120 mg/day MED  Call their attention to AMDG Guidelines and new WA state regulations  Associate medical director will meet with these docs personally
  • 29. Early opioids and disability in WA WC. Spine 2008; 33: 199-204  Population-based, prospective cohort  N=1843 workers with acute low back injury and at least 4 days lost time  Baseline interview within 18 days(median)  14% on disability at one year  Receipt of opioids for > 7 days, at least 2 Rxs, or > 150 mg MED doubled risk of 1 year disability, after adjustment for pain, function, injury severity
  • 30. Disability generated in workers‟ compensation may be a public health problem of the highest order  1954-4% of men 25-54 unemployed  2010-20% of men 25-54 unemployed  Federal (SSD) disability-8 million-will be bankrupt in 7 years  Workers‟ compensation is likely contributing a large proportion of the permanently unemployed/disabled to State, Federal and private disability programs David Leonhardt, Men, Unemployment, and disability, NYT, 4/8/2011
  • 32. Concrete steps to take  Track high MED and prescribers  Reverse permissive laws and set dosing standards for chronic, non-cancer pain  Implement AMDG Opioid Dosing Guidelines (http://www.agencymeddirectors.wa.gov/opioiddosing.asp)  Implement Prescription Monitoring Program  Encourage/incent use of best practices (web-based MED calculator, use of state PMPs)  DO NOT pay for office dispensed opioids  ID high prescribers and offer assistance  Incent community-based Rx alternatives (activity coaching and graded exercise early, opioid taper/multidisciplinary Rx later)  Offer assistance (academic detailing, free CME,ECHO)
  • 33. Unfinished business  Guidelines for peri-operative use of opioids  Looming large population dependent/addicted from Rx opioids  Develop guidelines Re tapering  PCP routine taper; Detox/pain clinic taper +/- buprenorphine  Rx of opioid use disorder/addiction New WA WC guidelines address these issues
  • 34. It‟s an emergency, so move ahead gingerly If you do something effective to reverse a decade of bad public policy, you will get pushback: Fauber J. Follow the money: Pain, policy, and profit. 2/19/12. URL:http://www.medpagetoday.com/Neurology/PainManag ement/31256  But remember that the docs in the trenches welcome assistance, tools, and best practices -National survey of PCP network for low income patients: 1/3 reported a severe outcome (death or life-threatening event); 1/3 do not initiate prescribing of opioids*  WA prescribers are MUCH more concerned about dependence/addiction than about regulatory scrutiny *Leverence RR, et al. J Am Board Fam Med 2011; 24: 551-561
  • 35. New state policies Connecticut WC policy-7/1/2012 The total daily dose of opioids should not be increased above 90mg oral MED/day (Morphine Equivalent Dose) unless the patient demonstrates measured improvement in function, pain or work capacity. Second opinion is recommended if contemplating raising the dose above 90 MED/day. MaineCare (Medicaid)-4/1/2012 Total 45 day maximum for non-cancer pain New Mexico-Rule 16.10.14-Proposed rules Aug, 2012 A health care practitioner shall, before prescribing, ordering, administering or dispensing a controlled substance listed in schedule II, III or IV, obtain a patient PMP report for the preceding twelve (12) months
  • 36. THANK YOU! For electronic copies of this presentation, please e-mail Melinda Fujiwara vasudha@u.washington.edu For questions or feedback, please e-mail Gary Franklin meddir@u.washington.edu

Notas del editor

  1. Within 1-2 years, however, unintentional deaths from opioids began to cross my desk in the WA workers compensation system. We then more systematically reviewed all deaths in our system, and published the first peer reviewed paper describing these deaths specifically related to prescribed opioids. These numbers are small because they occurred in the workers compensation population. At the same time, however, a similar trend involving fifty times as many deaths was occurring statewide.
  2. The vertical line in this figure indicates the date on which the Guidelines were released. We believe the Guidelines have already had an impact on substantially reducing the higher doses of the most potent, long-acting opioids in our workers compensation system.
  3. Our second strategy is legislation…The WA legislature passed legislation in March, 2010 that will repeal the currently permissive rules by June, 2011, and will implement new rules largely reflective of the dosing guidance and other best practices emphasized in the Guidelines. The lead sponsor, Rep Jim Moeller, is an addiction counselor who inherited dozens of patients on very high dose opioids when a “pill mill” in Vancouver, WA was shut down by the Drug Enforcement Agency. He had never previously seen these types of doses in his HMO practice, and became convinced that a new standard embodying best practices was needed.
  4. Besides the specific dosing guidance, all of the best practices are in common across all recent published opioid guidelines. There is some evidence of effectiveness of treatment agreements combined with urine drug screens, and some state insurers have reported decreased drug use with restrictions to single pharmacy and single providers.